[{"id":"f417a314-21f0-41ff-8280-309d00a9d454","acronym":"EAY131-Z1I","url":"https://clinicaltrials.gov/study/NCT04439227","created_at":"2021-01-18T21:22:09.573Z","updated_at":"2025-02-25T16:37:56.956Z","phase":"Phase 2","brief_title":"Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)","source_id_and_acronym":"NCT04439227 - EAY131-Z1I","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 03/13/2017","start_date":" 03/13/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"a170957e-b723-496d-b981-b2bbe36c4fc4","acronym":"EFFORT","url":"https://clinicaltrials.gov/study/NCT03579316","created_at":"2021-01-18T17:36:17.068Z","updated_at":"2025-02-25T17:29:43.272Z","phase":"Phase 2","brief_title":"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03579316 - EFFORT","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/07/2018","start_date":" 12/07/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-30"},{"id":"2d2751e6-8b4b-447b-8365-e4c1074e4966","acronym":"NCI-2014-00620","url":"https://clinicaltrials.gov/study/NCT02101775","created_at":"2021-01-18T09:42:38.823Z","updated_at":"2024-07-02T16:34:37.479Z","phase":"Phase 2","brief_title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02101775 - NCI-2014-00620","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • adavosertib (AZD1775) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 02/03/2022","primary_completion_date":" 02/03/2022","study_txt":" Completion: 02/20/2025","study_completion_date":" 02/20/2025","last_update_posted":"2024-06-07"},{"id":"6534f635-d546-46d9-bcee-4922c51c31eb","acronym":"NCI-2014-00620","url":"https://clinicaltrials.gov/study/NCT02151292","created_at":"2021-01-18T10:00:09.514Z","updated_at":"2024-07-02T16:34:37.200Z","phase":"Phase 2","brief_title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02151292 - NCI-2014-00620","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 02/03/2022","primary_completion_date":" 02/03/2022","study_txt":" Completion: 02/20/2025","study_completion_date":" 02/20/2025","last_update_posted":"2024-06-07"},{"id":"44ebbc97-9bac-4aa0-aaf1-361a99cfa91f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02659241","created_at":"2021-01-18T12:57:18.393Z","updated_at":"2024-07-02T16:35:09.936Z","phase":"Phase 1","brief_title":"Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02659241","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MUC16","pipe":" | ","alterations":" TP53 mutation • TP53 expression","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 02/04/2016","start_date":" 02/04/2016","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-04-12"},{"id":"326fc09f-923f-42f8-96c2-f5c6e69e46e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03284385","created_at":"2021-01-18T16:13:32.739Z","updated_at":"2024-07-02T16:35:13.144Z","phase":"Phase 2","brief_title":"Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2","source_id_and_acronym":"NCT03284385","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SETD2","pipe":" | ","alterations":" SETD2 mutation","tags":["SETD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SETD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-03-22"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"46c4dafa-648c-4f9b-8154-30165bb2495f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01849146","created_at":"2024-03-06T15:37:16.511Z","updated_at":"2024-07-02T16:35:16.074Z","phase":"Phase 1","brief_title":"Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma","source_id_and_acronym":"NCT01849146","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT • CASP3 • WEE1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • MGMT • CASP3 • WEE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/19/2013","start_date":" 08/19/2013","primary_txt":" Primary completion: 07/29/2021","primary_completion_date":" 07/29/2021","study_txt":" Completion: 03/04/2025","study_completion_date":" 03/04/2025","last_update_posted":"2024-03-06"},{"id":"91cb7612-511e-486c-a165-6d57df8ff07f","acronym":"VIOLETTE","url":"https://clinicaltrials.gov/study/NCT03330847","created_at":"2021-01-17T17:33:58.725Z","updated_at":"2024-07-02T16:35:16.588Z","phase":"Phase 2","brief_title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","source_id_and_acronym":"NCT03330847 - VIOLETTE","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • HRD","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 273","initiation":"Initiation: 03/07/2018","start_date":" 03/07/2018","primary_txt":" Primary completion: 11/13/2020","primary_completion_date":" 11/13/2020","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-04"},{"id":"18e195bd-a363-4962-a92f-51fac52b0f0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04197713","created_at":"2021-01-18T20:27:25.308Z","updated_at":"2024-07-02T16:35:30.028Z","phase":"Phase 1","brief_title":"Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study","source_id_and_acronym":"NCT04197713","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • FANCA • BRIP1 • CD4","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • CCNE1 amplification • BRIP1 mutation • FANCA mutation","tags":["BRCA1 • BRCA2 • FANCA • BRIP1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • CCNE1 amplification • BRIP1 mutation • FANCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2023-11-08"},{"id":"37f91647-0805-4a4c-8991-be19e1ffd9fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03253679","created_at":"2021-01-18T16:04:25.042Z","updated_at":"2024-07-02T16:35:33.239Z","phase":"Phase 2","brief_title":"AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification","source_id_and_acronym":"NCT03253679","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCNE1","pipe":" | ","alterations":" CCNE1 amplification","tags":["CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCNE1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2023-10-17"},{"id":"7d38238f-0360-4cbf-a047-99f5bdad7662","acronym":"","url":"https://clinicaltrials.gov/study/NCT02272790","created_at":"2021-01-18T10:41:27.352Z","updated_at":"2024-07-02T16:35:34.901Z","phase":"Phase 2","brief_title":"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02272790","lead_sponsor":"AstraZeneca","biomarkers":" CYP1A2","pipe":"","alterations":" ","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • adavosertib (AZD1775) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/30/2015","start_date":" 01/30/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 03/08/2023","study_completion_date":" 03/08/2023","last_update_posted":"2023-10-03"},{"id":"ec6fbe22-b1c8-44d5-90ef-3b484be78199","acronym":"","url":"https://clinicaltrials.gov/study/NCT01827384","created_at":"2021-01-18T08:07:17.493Z","updated_at":"2024-07-02T16:35:35.234Z","phase":"Phase 2","brief_title":"MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations","source_id_and_acronym":"NCT01827384","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • carboplatin • everolimus • temozolomide • adavosertib (AZD1775) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 01/07/2014","start_date":" 01/07/2014","primary_txt":" Primary completion: 06/19/2021","primary_completion_date":" 06/19/2021","study_txt":" Completion: 10/08/2021","study_completion_date":" 10/08/2021","last_update_posted":"2023-09-29"},{"id":"651d0d4a-82d5-4879-b462-51d86f620e38","acronym":"","url":"https://clinicaltrials.gov/study/NCT02095132","created_at":"2021-01-18T09:40:11.812Z","updated_at":"2024-07-02T16:35:35.775Z","phase":"Phase 1/2","brief_title":"Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT02095132","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • AFP","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775) • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 03/28/2014","start_date":" 03/28/2014","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-09-26"},{"id":"93a94b53-4570-4860-a4f6-00aaaac1d92f","acronym":"MK-1775-001","url":"https://clinicaltrials.gov/study/NCT00648648","created_at":"2021-01-18T02:24:46.554Z","updated_at":"2024-07-02T16:35:36.517Z","phase":"Phase 1","brief_title":"A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)","source_id_and_acronym":"NCT00648648 - MK-1775-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" CDK1","pipe":"","alterations":" ","tags":["CDK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 02/25/2008","start_date":" 02/25/2008","primary_txt":" Primary completion: 01/06/2014","primary_completion_date":" 01/06/2014","study_txt":" Completion: 01/06/2014","study_completion_date":" 01/06/2014","last_update_posted":"2023-09-21"},{"id":"eee52d84-174d-4b32-9e9a-731b67d54fb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02482311","created_at":"2021-01-18T11:57:16.735Z","updated_at":"2024-07-02T16:35:44.114Z","phase":"Phase 1","brief_title":"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT02482311","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA wild-type","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 08/22/2019","study_completion_date":" 08/22/2019","last_update_posted":"2023-07-03"},{"id":"fa6c4a73-ac0c-428c-81c9-9eb06eb26591","acronym":"","url":"https://clinicaltrials.gov/study/NCT02448329","created_at":"2021-01-18T11:44:22.181Z","updated_at":"2024-07-02T16:36:08.887Z","phase":"Phase 2","brief_title":"Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy","source_id_and_acronym":"NCT02448329","lead_sponsor":"Samsung Medical Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 04/19/2021","study_completion_date":" 04/19/2021","last_update_posted":"2022-06-15"},{"id":"978f57b5-814a-4f03-baf8-c08db089ecd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03012477","created_at":"2021-01-18T14:49:23.904Z","updated_at":"2025-02-25T15:07:31.381Z","phase":"Phase 2","brief_title":"CISPLATIN + AZD-1775 In Breast Cancer","source_id_and_acronym":"NCT03012477","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • TP53 • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" TP53 mutation • HER-2 negative","tags":["HER-2 • TP53 • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 05/07/2019","primary_completion_date":" 05/07/2019","study_txt":" Completion: 11/30/2020","study_completion_date":" 11/30/2020","last_update_posted":"2021-11-23"},{"id":"c053a37c-5fea-4975-bc13-df33de5dd57e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01748825","created_at":"2021-01-18T07:40:14.526Z","updated_at":"2024-07-02T16:36:27.478Z","phase":"Phase 1","brief_title":"AZD1775 for Advanced Solid Tumors","source_id_and_acronym":"NCT01748825","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 12/19/2012","start_date":" 12/19/2012","primary_txt":" Primary completion: 05/19/2020","primary_completion_date":" 05/19/2020","study_txt":" Completion: 05/19/2020","study_completion_date":" 05/19/2020","last_update_posted":"2021-07-26"},{"id":"86997ced-5298-43a4-9224-06ed854047c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02207010","created_at":"2021-01-18T10:20:00.773Z","updated_at":"2024-07-02T16:36:37.524Z","phase":"Phase 1","brief_title":"A Phase 0 Study of AZD1775 in Recurrent GBM Patients","source_id_and_acronym":"NCT02207010","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" CDK1","pipe":"","alterations":" ","tags":["CDK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 12/31/2015","primary_completion_date":" 12/31/2015","study_txt":" Completion: 03/25/2019","study_completion_date":" 03/25/2019","last_update_posted":"2020-12-10"},{"id":"10edf80e-2175-4505-90ce-d35cfc5f93db","acronym":"","url":"https://clinicaltrials.gov/study/NCT02906059","created_at":"2021-01-18T14:15:37.961Z","updated_at":"2025-02-25T15:07:18.618Z","phase":"Phase 1","brief_title":"Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02906059","lead_sponsor":"NYU Langone Health","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775) • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 03/12/2020","primary_completion_date":" 03/12/2020","study_txt":" Completion: 03/12/2020","study_completion_date":" 03/12/2020","last_update_posted":"2020-10-12"},{"id":"d7d21f29-e3c8-43ec-a65b-91985a4a991e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03333824","created_at":"2021-01-18T16:27:44.837Z","updated_at":"2024-07-02T16:37:01.370Z","phase":"Phase 1","brief_title":"Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer","source_id_and_acronym":"NCT03333824","lead_sponsor":"AstraZeneca","biomarkers":" CYP1A2","pipe":"","alterations":" ","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775) • granisetron oral • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/22/2019","primary_completion_date":" 01/22/2019","study_txt":" Completion: 01/22/2019","study_completion_date":" 01/22/2019","last_update_posted":"2019-03-25"},{"id":"86c7e516-a401-4172-8a1d-761e68df3f75","acronym":"","url":"https://clinicaltrials.gov/study/NCT02508246","created_at":"2021-01-18T12:06:32.397Z","updated_at":"2024-07-02T16:37:01.968Z","phase":"Phase 1","brief_title":"WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT02508246","lead_sponsor":"University of Washington","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 07/22/2015","start_date":" 07/22/2015","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 04/26/2018","study_completion_date":" 04/26/2018","last_update_posted":"2019-03-13"}]